Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis—the PMEP trial: study protocol for a randomized controlled trial

Table 2 Study interventions

Intervention arm (n = 20)	Placebo arm (n = 20)	All study participants (Intervention + Placebo arms)
● Vancomycin: 250 mg/5 cc sterile water nebulized two times a day, Days 1–28	● Placebo: quinine 0.5 mg/5 cc sterile water nebulized two times a day, Days 1–28	● Oral Rifampin: Days 1–28
		● 1. >45 kg: 600 mg by mouth daily
		● 2. 35–45 kg: 450 mg by mouth daily
		● 3. 25–34.9 kg: 300 mg by mouth daily
		● Oral TMP/SMX^a (DS-160/800): Days 1–28	OR	● Oral Doxycycline^b: Days 1–28
		● 1. >45 kg: Two DS tabs by mouth twice a day		● 1. >45 kg: 100 mg by mouth twice a day
		● 2. 25–45 kg: One DS tab by mouth twice a day		● 1. 35–45 kg: 75 mg by mouth twice a day
				● 2. 35–45 kg: 75 mg by mouth twice a day
		● Mupirocin 2% intranasal ointment: apply to each nasal cavity twice a day for Days 1–5 of study
		● Hibiclens (4% chlorhexidine gluconate) liquid skin cleanser: use three packets once weekly in the shower, Days 1–28
		● Wipe down of high touch household surfaces with Sani-Cloth Alcohol Free Germicidal wipes: use once a week, Days 1–28
		● Wash all linen and towels in hot water: weekly, Days 1–21

^aParticipants with MRSA susceptible by MIC testing to TMP/SMX and without history of sulfa allergy will be treated with trimethoprim/sulfamethoxazole.
^bParticipants with MRSA resistant by MIC testing to TMP/SMX and without history of doxycycline allergy will be treated with doxycycline.

ISSN: 1745-6215